A Surge of First-in-Class and Novel Approvals
From January to August 2025, the FDA approved 25 novel drugs – nearly one per week – reflecting an unprecedented pace in expanding treatment options across therapeutic areas
Key Highlights:
Datroway (datopotamab deruxtecan-dlnk): Approved January 17 for HER2-negative, hormone receptor-positive metastatic breast cancer – a first-in-class antibody-drug conjugate targeting Trop-2 U.S. Food and Drug AdministrationWikipedia.
Suzetrigine (Journavx): Approved January 30 as a novel non-opioid painkiller for moderate to severe acute pain, matching opioid efficacy without addiction or sedation concerns U.S. Food and Drug AdministrationWikipedia.
Gomekli (mirdametinib): Approved February 11 for neurofibromatosis type 1 with plexiform neurofibromas not amenable to resection U.S. Food and Drug AdministrationWikipedia.
Modeyso (dordaviprone): Approved August 6 as the first systemic therapy for the aggressive brain cancer diffuse midline glioma (DMG) with H3 K27M mutation U.S. Food and Drug AdministrationReuters.
Brinsupri (brensocatib): Approved August 12 for non-cystic fibrosis bronchiectasis, marking the first treatment for this chronic condition
This list also includes treatments for presbyopia (Vizz), phenylketonuria (Sephience), chronic hand eczema (Anzupgo), hereditary angioedema (Ekterly, Andembry), hypertension (Widaplik), HIV PrEP (Yeztugo), bladder cancer (Zusduri), multiple myeloma (Lynozyfic), and more
Themes & Therapeutic Trends
Precision oncology is prominent—many approvals target specific mutations or biomarkers (e.g., ROS1-positive NSCLC, HER2 mutation-positive NSCLC, H3 K27M-mutant DMG).
First-in-class therapies like datopotamab and suzetrigine signal major innovation in both oncology and pain management.
Non-opioid pain relief: Suzetrigine addresses acute surgical pain with opioid-level efficacy minus typical opioid risks.
Rare and unmet needs: Modeyso, migraine treatments, and hereditary angioedema options reflect focus on conditions lacking effective therapies.
Convenience & accessibility: Approvals like prefilled injections, at-home PrEP (Yeztugo), and self-administered formulations aim to improve patient adherence and reach.
FDA Strategy: Fast-Tracking and Flexibility
The FDA is evolving its approach:
“National priority vouchers”: A new mechanism to expedite review for treatments addressing critical health needs, offering faster timelines (1–2 months vs. typical 6–10 months) and streamlined communication AP News.
Rare disease flexibility: The agency may allow reduced trial requirements, even bypassing randomized studies in certain contexts AP News.
Leadership dynamics: Internal turnover—such as Vinay Prasad’s abrupt reinstatement to lead the biologics center—has created regulatory unpredictability, affecting investor sentiment Barron’sFinancial Times.
Support for innovation: Commissioner Makary has endorsed accelerating rare disease drug approvals, reducing animal testing, and keeping science-based decision-making while minimizing pharma influence
Implications and Outlook
For Patients and Providers:
A diverse array of newer, more precise treatment options are now available.
Patient-centered improvements—like non-opioid analgesics and home-administerable therapies—enhance care access and safety.
For Biotech and Pharma:
The FDA’s evolving incentives and expedited pathways create both opportunity and uncertainty.
Political and leadership instability may complicate strategic planning for companies.
For Investors and Healthcare Systems:
Biotech stocks remain reactive to FDA developments and internal restructuring.
Payers and policy experts will need to assess these new therapies’ budget impact and cost-effectiveness, especially with multiple first-in-class drugs emerging
